Biogen’s Aducanumab: Why Accelerated Approval Might, And Might Not, Be An Option For US FDA

 
• By Sue Sutter
conflict in business concept with broken chain
US FDA's advisory committee saw a disconnect between Alzheimer's biomarker data and aducanumab's clinical effects. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers